JW (Cayman) Therapeutics Co. Ltd. (2126) Price & Analysis

Compare

0 Followers

2126 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$1.19 - HK$2.68

Previous CloseN/A

Volume104.00K

Average Volume (3M)1.96M

Market Cap

HK$615.84M

Enterprise ValueHK$284.74M

Total Cash (Recent Filing)¥288.99M

Total Debt (Recent Filing)¥1.68B

Price to Earnings (P/E)―

Beta1.51

Next Earnings

Sep 02, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.55

Shares Outstanding416,106,450

10 Day Avg. Volume1,625,419

30 Day Avg. Volume1,963,400

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)13.58

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

---

JW (Cayman) Therapeutics Co. Ltd. News

PremiumCompany Announcements

JW Therapeutics Grants Over 7 Million Share Options to Employees

4d ago

PremiumCompany Announcements

JW Therapeutics Reports 2024 Financial Results Amid Strategic Adjustments

19d ago

PremiumCompany Announcements

JW Therapeutics Enters Material Transfer Agreement with Juno

28d ago

PremiumCompany Announcements

JW Therapeutics Schedules Board Meeting for Financial Review

30d ago

PremiumCompany Announcements

JW Therapeutics Appoints New Chairman, Emphasizes Strategic Continuity

1M ago

PremiumCompany Announcements

JW Therapeutics’ Carteyva® Receives Breakthrough Therapy Designation in China

3M ago

PremiumCompany Announcements

JW Therapeutics Grants Share Options and Restricted Units to Employees

3M ago

PremiumCompany Announcements

JW Cayman Therapeutics Appoints Deloitte as New Auditor

6M ago

See All HK:2126 News

---

Financials

Quarterly

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

0.03%

Mutual Funds

― Other Institutional Investors

99.97% Public Companies and

Individual Investors

Detailed Ownership Overview >

2126 FAQ

What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?

JW (Cayman) Therapeutics Co. Ltd. lowest stock price was HK$1.19 and its highest was HK$2.68 in the past 12 months.

What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?

JW (Cayman) Therapeutics Co. Ltd.’s market cap is HK$615.84M.

When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?

JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date is Sep 02, 2025 which is in 140 days.

How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?

JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Mar 27, 2025. The company reported -HK$0.918 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.918.

Is JW (Cayman) Therapeutics Co. Ltd. overvalued?

According to Wall Street analysts JW (Cayman) Therapeutics Co. Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?

JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.

What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?

JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?

JW (Cayman) Therapeutics Co. Ltd. has 416,106,450 shares outstanding.

What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?

JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -HK$0.918 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.319%.

Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?

Currently, no hedge funds are holding shares in HK:2126

---

JW (Cayman) Therapeutics Co. Ltd. Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

-41.34%

Trailing 12-Months

Asset Growth

-24.32%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

JW (Cayman) Therapeutics Co. Ltd.

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

---

2126 Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2022","6":"Mar<br/>2023","9":"Jun<br/>2023","12":"Aug<br/>2023","25":"Aug<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.82,2.603076923076923,2.386153846153846,2.169230769230769,1.9523076923076923,1.7353846153846153,1.5184615384615383,1.3015384615384615,1.0846153846153845,0.8676923076923075,0.6507692307692308,0.433846153846154,0.21692307692307677,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.2,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.16,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.1,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.52,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.35,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.43,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.46,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.65,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.26,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.97,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.57,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.82,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.82,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >